[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gynecologic-tumor\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gynecologic-tumor":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,77,108],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":76},"100368284","the-momentum-study-the-multiple-outcome-evaluation-of-radiation-therapy-using-the-mr-linac-study-100368284",false,"NCT04075305","The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study","The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study","MOMENTUM","Inclusion Criteria:\n\n* Patient is to undergo or has completed imaging or treatment procedures on an MR-Linac;\n* Patient provides written, informed consent;\n* Patient is 18 years old or older.\n\nExclusion Criteria:\n\n* MRI exclusion criteria, including\n* MRI contraindications as per usual clinical care, such as (possible) pregnancy; claustrophobia and metal or electronic implants not compatible with MRI.","ALL","18 Years",{"count":20,"type":21},8000,"ESTIMATED","2 Years","OBSERVATIONAL","The Multi-OutcoMe EvaluatioN of radiation Therapy Using the Unity MR-Linac Study (MOMENTUM) is a multi-institutional, international registry facilitating evidenced based implementation of the Unity MR-Linac technology and further technical development of the MR-Linac system with the ultimate purpose to improve patients' survival, local, and regional tumor control and quality of life.",[26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63],"Oncology","Breast Cancer","Prostate Cancer","Gynecologic Cancer","Brain Tumor","Brain Cancer","Gynecologic Tumor","Prostate Tumor","Prostate Neoplasm","Breast Tumor","Radiation Toxicity","Quality of Life","Rectal Cancer","Rectal Tumor","Rectal Neoplasms","Lung Cancer","Lung Tumor","Lung Neoplasm","Esophageal Cancer","Esophagus Cancer","Esophageal Tumor","Esophageal Neoplasm","Esophagus Tumor","Esophagus Neoplasm","Pancreatic Cancer","Pancreatic Tumor","Pancreatic Neoplasms","Head and Neck Cancer","Head and Neck Neoplasms","Head and Neck Tumor","Tumor","Neoplasms","Bladder Cancer","Bladder Neoplasm","Liver Cancer","Liver Neoplasms","Liver Metastases","Oligometastases","RECRUITING","2026-03-03",{"date":67,"type":68},"2026-03-05","ACTUAL",{"date":70,"type":68},"2019-02-01",{"date":72,"type":21},"2030-08-01",{"name":74,"class":75},"UMC Utrecht","OTHER",18,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":84,"minAge":18,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":87,"conditions":88,"keywords":94,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":107},"100613529","contribution-of-oncovascular-surgery-in-the-treatment-of-gynecological-advanced-malignant-diseases-100613529","NCT07267780","Contribution of Oncovascular Surgery in the Treatment of Gynecological Advanced Malignant Diseases.","The Contribution of Oncovascular Surgery in the Treatment of Gynecological Advanced Malignant Diseases: a Prospective and Retrospective Multicenter Study","Inclusion Criteria:\n\n\\- Retrospective Arm:\n\n1. Diagnosis of advanced or recurrent gynecologic cancer with vascular involvement requiring resection and\u002For reconstruction of major blood vessels, including:\n\n   * Ovarian carcinoma\n   * Cervical carcinoma\n   * Endometrial carcinoma\n   * Vulvar carcinoma\n   * Uterine or other types of sarcomas with vascular involvement\n2. Documented major vascular invasion, confirmed by preoperative imaging or intraoperative description.\n3. Patients who underwent onco-vascular surgery for advanced or recurrent gynecologic cancers between January 1, 2017, and August 31, 2025.\n4. Data Protection Impact Assessment (DPIA) approved for the management of retrospective data. (Deceased or untraceable patients will also be included to avoid selection bias, in accordance with Article 110 bis, paragraph 4 of the Italian Privacy Code. A DPIA will be produced and published on the Sponsor's website before study initiation, and patients who explicitly objected before death will not be included.)\n\nProspective Arm:\n\n1. Age ≥18 years\n2. Patients eligible for onco-vascular surgery for advanced or recurrent gynecologic cancers with vascular involvement, including:\n\n   * Ovarian carcinoma\n   * Cervical carcinoma\n   * Endometrial carcinoma\n   * Vulvar carcinoma\n   * Uterine or other types of sarcomas\n3. Documented major vascular invasion, confirmed by preoperative imaging or intraoperative description.\n4. Signed informed consent.\n\nExclusion Criteria:\n\n1. Patients younger than 18 years of age\n2. Patients with early-stage gynecologic cancers not eligible for onco-vascular surgery\n3. Patients undergoing vascular resection due to accidental injury of blood vessels not directly related to tumor infiltration.\n4. Patients who have previously undergone vascular surgery for reasons unrelated to the study, to avoid data overlap.","FEMALE",{"count":86,"type":21},130,"Multicenter ambispective observational study (prospective\u002Fretrospective)",[89,90,91,92,93,32],"Ovarian Carcinoma","Cervical Carcinoma","Endometrial Carcinoma","Vulvar Carcinoma","Uterine Sarcoma",[95,96],"Advanced or recurrent gynecologic tumor","Vascular infiltration","NOT_YET_RECRUITING","2025-11-25",{"date":100,"type":68},"2025-12-05",{"date":102,"type":21},"2025-12",{"date":104,"type":21},"2035-12",{"name":106,"class":75},"National Cancer Institute, Naples",2,{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":118,"phases":119,"briefSummary":121,"conditions":122,"keywords":127,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":143},"100443348","a-study-evaluating-the-integrative-medicine-at-home-imhome-program-in-people-with-cancer-100443348","NCT05053230","A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer","Integrative Medicine for Patient-reported Outcomes, Values, and Experience (IMPROVE)","IMPROVE","Inclusion Criteria:\n\n* Age ≥ 18 years or older\n* Karnofsky score 60 or greater\n* Life expectancy greater than six months\n* English speaking\n\nAdditional Inclusion Criteria for Head and Neck, Thoracic, Gynecologic, Melanoma and Breast Baskets\n\n* Patients with a diagnosis of head and neck tumors, thoracic tumors, gynecological tumors, melanoma, breast cancer, or gynecologic cancer\n* Actively receiving systemic oncological treatment or radiotherapy, or within 4 weeks of radiotherapy completion or primary cytoreductive surgery\n* Worst fatigue over the last 7 days rated 4 or greater on (0-10 scale)\n\nAdditional Inclusion Criteria for First Remission Gynecologic Cancer Basket\n\n* Patients with a diagnosis or clinical suspicion of gynecologic malignancy who have completed definitive first line treatment (maintenance hormonal or targeted therapies are allowed)\n\nAdditional Inclusion Criteria for the Advanced Cancer Basket:\n\n* Patients with a diagnosis of Stage III or IV lung cancer; any stage pancreatic cancer, unresectable cholangiocarcinoma, unresectable liver cancer, unresectable ampullary or peri-ampullary cancer, or other stage IV gastrointestinal cancer; stage III or IV ovarian or fallopian tube cancers or other stage IV gynecologic cancer; stage IV breast cancer; stage III testicular cancer or any stage IV genitourinary cancer; stage IV sarcoma; stage IV melanoma; stage IV endocrine cancer; lymphoma, myeloma, or Leukemia\n* Actively receiving oncological treatment, radiotherapy or active surveillance\n\nAdditional Inclusion Criteria for the Cancer Survivor Basket:\n\n* Completed active cancer treatment (e.g., surgery, radiation, chemotherapy) (maintenance hormonal or targeted therapies are allowed).\n* Worst fatigue over the last 7 days rated 4 or greater on (0-10 scale)\n\nExclusion Criteria:\n\n* Cognitive impairment that would preclude response to study assessments or require the use of Legally Authorized Representatives\n* Unwilling to accept random assignment\n* Concurrently enroll onto ongoing competing trials of integrative medicine interventions with symptom\u002Ftoxicity as primary outcome. Note, however, patient will be allowed to enroll on other therapeutic protocols",{"count":117,"type":21},480,"INTERVENTIONAL",[120],"NA","The overarching long-term goal of the Integrative Medicine for Patient-reported Outcomes Values and Experience (IMPROVE) research program is to evaluate whether integrating a virtual mind-body programming, Integrative Medicine at Home (IM@Home), will improve patient perceived values, outcomes, and experiences as they undergo systemic cancer treatment such as chemotherapy, immunotherapy, radiotherapy, targeted agents, cytoreductive surgery.",[53,55,123,124,29,32,125,126],"Thoracic Tumor","Thoracic Cancer","Melanoma","Ovarian Cancer",[53,128,129,130,131,132,133,134],"head and neck tumor","thoracic tumors","gynecological tumors","melanoma","21-369","Memorial Sloan Kettering Cancer Center","ovarian cancer","2025-10-08",{"date":137,"type":68},"2025-10-09",{"date":139,"type":68},"2021-09-20",{"date":141,"type":21},"2026-09-20",{"name":133,"class":75},7]